Lonza has expanded its integrated DNA-to-IND biologics development offering, introducing new capabilities designed to accelerate early-stage decision-making and reduce development risk for monoclonal antibody and other biologics programmes.

The enhanced approach combines early development, manufacturing and regulatory insights to support faster progression from discovery to first-in-human studies, with the company stating that toxicology material can be delivered in approximately two months and IND readiness achieved in as little as six months.

The strategy is centred on providing early-stage, data-driven insights intended to improve confidence in candidate selection and streamline development pathways at a point where decisions have significant downstream impact on cost, timeline and manufacturability.

Lonza said the updated offering builds on its established preclinical development platform and integrates process development and manufacturing expertise earlier in the workflow to support more predictable scale-up and regulatory planning.

A key component of the expanded package is a new vector technology, GS Ori-Go, which has been developed to improve productivity and consistency in early-stage biomanufacturing. The system is based on Lonza’s established GS expression platform, which has been used in the development of more than 100 commercial biologic products.

According to Lonza, GS Ori-Go supports higher production cell line performance, with reported titres exceeding 11 g/L in lead clones and improved bulk pool stability. The company said the system enables a simplified workflow by allowing progression from bulk pools directly to clonal cell lines, removing intermediate selection steps.

Lonza also reported productivity improvements of more than 30% across multiple biologic modalities, including monoclonal antibodies, bispecifics and fusion proteins, alongside shortened cell line development timelines.

The company said these advances are intended to improve both speed and predictability in early biologics development, while maintaining quality and regulatory compliance standards required for clinical progression.

Raymond Donninger, senior director of commercial development for integrated biologics at Lonza, said: “We know that the earliest decisions in biologics development are often the hardest and the most critical.

“With this enhanced DNA-to-IND offering, we’re helping our customers make those decisions sooner and with greater clarity, while bringing meaningful innovation to them faster. By combining early de-risking, accelerated execution, and technologies like our new GS Ori-Go vectors, we’re enabling teams to progress high-quality biologics programmes to the clinic with greater speed, confidence, and control.”

Lonza said the strengthened offering reflects broader industry demand for integrated development models that reduce uncertainty in early-stage biologics programmes and shorten the path from discovery to clinical entry.